Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY BETH SCHOLAND

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1639269251
CMS profile
608915
Location
SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$94,490.39

104 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $35,890.50 34
United Therapeutics Corporation $30,832.75 31
Boehringer Ingelheim Pharmaceuticals, Inc. $19,842.88 18
E.R. Squibb & Sons, L.L.C. $3,020.00 1
ABBVIE INC. $3,018.15 2
Merck Sharp & Dohme LLC $1,413.07 11
Insmed, Inc. $473.04 7

Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY BETH SCHOLAND

NPI 1639269251 · CMS profile ID 608915

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SALT LAKE CITY, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639269251?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY BETH SCHOLAND, NPI 1639269251, CMS profile ID 608915. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639269251?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MARY BETH SCHOLAND, NPI 1639269251, CMS profile ID 608915. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639269251?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MARY BETH SCHOLAND, NPI 1639269251, CMS profile ID 608915, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–104 of 104 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1639269251?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

104 matching records · $94,490.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 104 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–104 of 104.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
United Therapeutics Corporation $143.5001/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242548102 CMS
United Therapeutics Corporation $579.4901/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242550158 CMS
United Therapeutics Corporation $368.8301/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242550166 CMS
United Therapeutics Corporation $22.8501/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242550170 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,289.65 21
PY2020 $7,842.50 5
PY2021 $30,947.72 27
PY2022 $40,959.88 48
PY2023 $58,810.97 69
PY2024 $76,519.93 79
PY2025 $94,490.39 104

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,400.00 3
PY2025 Principal investigator $408,598.41 127
PY2024 Recipient $49,994.67 4
PY2024 Principal investigator $663,454.23 61
PY2023 Recipient $2,130.96 2
PY2023 Principal investigator $657,833.19 34
PY2022 Recipient $112.63 1
PY2022 Principal investigator $503,922.06 23
PY2021 Principal investigator $176,792.58 78
PY2020 Recipient $2,745.83 1
PY2020 Principal investigator $85,351.91 52
PY2019 Principal investigator $223,594.47 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

130 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $313.56 12/31/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792065
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $131.10 12/31/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry No dispute reported 06/30/2026 1220792067
Principal investigator 1 United Therapeutics Corporation $1,952.25 12/24/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383317
Principal investigator 1 United Therapeutics Corporation $4,565.70 12/24/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383333
Principal investigator 1 United Therapeutics Corporation $6,242.40 12/24/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383339
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,717.00 12/03/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220792071
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643517
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643519
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 12/01/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220792061
Principal investigator 1 United Therapeutics Corporation $616.50 11/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383307
Principal investigator 1 United Therapeutics Corporation $1,746.75 11/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383313
Principal investigator 1 United Therapeutics Corporation $4,085.10 11/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383331
Principal investigator 1 United Therapeutics Corporation $16,043.40 11/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383351
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 11/19/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643521
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643523
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 11/19/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643525
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 11/19/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643527
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 11/19/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643529
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,349.80 11/13/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792053
Principal investigator 1 United Therapeutics Corporation $5,754.00 11/12/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383323
Principal investigator 1 United Therapeutics Corporation $13,456.80 11/12/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383349
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643513
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643515
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15.00 11/01/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220792059
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626847
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626849
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626851
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626853
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626855
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626857
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626859
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626861
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 10/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220626863
Principal investigator 1 United Therapeutics Corporation $1,808.40 10/22/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383315
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643507
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643509
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643511
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3.87 10/01/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220792063
Principal investigator 1 GlaxoSmithKline, LLC. $2,300.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192153248
Principal investigator 1 GlaxoSmithKline, LLC. $2,700.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192153252
Principal investigator 1 GlaxoSmithKline, LLC. $2,725.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192153257
Principal investigator 1 GlaxoSmithKline, LLC. $2,457.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156002
Principal investigator 1 GlaxoSmithKline, LLC. $5,400.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156006
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156010
Principal investigator 1 GlaxoSmithKline, LLC. $7,000.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156014
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156018
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156022
Principal investigator 1 GlaxoSmithKline, LLC. $458.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156026
Principal investigator 1 GlaxoSmithKline, LLC. $4,555.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156030
Principal investigator 1 GlaxoSmithKline, LLC. $10,800.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156567
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 10/01/2025 Non-covered Recipient Entity
UNIVERSITY OF UTAH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192156575
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,592.10 09/24/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220792057
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,881.80 09/18/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792051
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643503
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643505
Recipient Boehringer Ingelheim International GmbH $500.00 09/01/2025 Covered Recipient Physician A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220692443
Principal investigator 1 United Therapeutics Corporation $616.50 08/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383305
Principal investigator 1 United Therapeutics Corporation $4,617.00 08/27/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383337
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643499
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643501
Principal investigator 1 United Therapeutics Corporation $6,966.00 07/23/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383341
Recipient United Therapeutics Corporation $580.00 07/08/2025 Covered Recipient Physician PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380088
Principal investigator 1 United Therapeutics Corporation $3,699.00 07/08/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383321
Principal investigator 1 United Therapeutics Corporation $8,650.80 07/08/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383345
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643495
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643497
Principal investigator 1 United Therapeutics Corporation $616.50 06/25/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383303
Principal investigator 1 United Therapeutics Corporation $4,617.00 06/25/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383335
Principal investigator 1 United Therapeutics Corporation $3,082.50 06/11/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383319
Principal investigator 1 United Therapeutics Corporation $7,209.00 06/11/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383343
Principal investigator 1 Boehringer Ingelheim International GmbH $35.41 06/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643481
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643483
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643485
Principal investigator 1 Genentech, Inc. $6,480.00 05/27/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211558342
Principal investigator 1 Genentech, Inc. $270.00 05/27/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211558346
Principal investigator 1 Genentech, Inc. $3,300.00 05/27/2025 Covered Recipient Teaching Hospital
U Of Utah Neuropsychiatric Institute
Phase 2 Double Blind Randomized Study in IPF and SSc ILD No dispute reported 06/30/2026 1211558351
Principal investigator 1 United Therapeutics Corporation $12,937.05 05/21/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383347
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,749.40 05/09/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792049
Principal investigator 1 United Therapeutics Corporation $616.50 05/07/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383301
Principal investigator 1 United Therapeutics Corporation $1,746.75 05/07/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383311
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643477
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643479
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 04/23/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643487
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 04/23/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643489
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 04/23/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643491
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 04/23/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643493
Principal investigator 1 United Therapeutics Corporation $4,085.10 04/23/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383329
Principal investigator 1 United Therapeutics Corporation $18,058.95 04/23/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383353
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $48,472.00 04/13/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792047
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,661.77 04/10/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1236000060
Recipient United Therapeutics Corporation $2,320.00 04/09/2025 Covered Recipient Physician PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380090
Principal investigator 1 United Therapeutics Corporation $1,027.50 04/09/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383309
Principal investigator 1 United Therapeutics Corporation $2,160.00 04/09/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383325
Principal investigator 1 United Therapeutics Corporation $2,403.00 04/09/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383327
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16.86 04/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220793645
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,213.10 03/19/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792045
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643557
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643559
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 03/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220793643
Principal investigator 1 United Therapeutics Corporation $616.50 02/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383285
Principal investigator 1 United Therapeutics Corporation $2,055.00 02/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383287
Principal investigator 1 United Therapeutics Corporation $4,806.00 02/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383295
Principal investigator 1 United Therapeutics Corporation $27,761.40 02/26/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383299
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 02/25/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643469
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643471
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 02/25/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643473
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 02/25/2025 Non-covered Recipient Entity
University Of Utah Hht Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220643475
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,266.80 02/14/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220792043
Principal investigator 1 United Therapeutics Corporation $3,390.75 02/12/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383289
Principal investigator 1 United Therapeutics Corporation $9,105.02 02/12/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383291
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 02/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643541
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 02/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643543
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 02/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643545
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643547
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643549
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 02/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220793641
Principal investigator 1 United Therapeutics Corporation $340.20 01/29/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383293
Principal investigator 1 United Therapeutics Corporation $7,929.90 01/29/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242383297
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 01/27/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643551
Principal investigator 1 Boehringer Ingelheim International GmbH $14.02 01/27/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643553
Principal investigator 1 Boehringer Ingelheim International GmbH $1.60 01/27/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643555
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,845.60 01/21/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220792069
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $64,794.21 01/13/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1236000058
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,376.70 01/07/2025 Covered Recipient Teaching Hospital
U Of U Hospitals & Clinics
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220792055
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 01/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643531
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 01/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643533
Principal investigator 1 Boehringer Ingelheim International GmbH $14.16 01/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643535
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643537
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220643539
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 01/01/2025 Non-covered Recipient Entity
University Of Utah Hht Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220793639